Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.38%
#2 Victoria VR Victoria VR +11.93%
#3 Movement Movement +11.39%
#4 Palladium Network Palladium Network +9.28%
#5 DMT-NAT DMT-NAT +6.25%
#6 Cryptopia Cryptopia +4.73%
#7 Pons Pons +4.23%
#8 GRVT Token GRVT Token +3.85%
#9 MarsCoin MarsCoin +3.69%
#10 COTI COTI +3.65%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Rank in Stocks #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Share Price
$0.0009
Last synced: 2025-05-27
Market Cap
$1.15K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Arch Therapeutics, Inc. (ARTH)

Category

Healthcare
Revenue for Arch Therapeutics, Inc. (ARTH)
Revenue in Jun 2024 TTM: $148.16K
According to Arch Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $148.16K. In 2022 the company made a revenue of $15.65K an increase over the revenue in the year 2021 that was $11.57K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Arch Therapeutics, Inc. from 2011 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $148.16K 95.66%
2023 $75.72K 383.80%
2022 $15.65K 35.34%
2021 $11.57K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,520,448.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 4,063,861.52%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 6,823,996.90%
BE